Omalizumab for the Treatment of Atopic Dermatitis

Martínez, M.C. Fernández-Antón; Leis-Dosil, V.M.; Alfageme‐Roldán, F.; Paravisini, Alexandra; Sánchez‐Ramón, Silvia; Fernández, Rafael Ramos

doi:10.1016/j.adengl.2012.08.002

Cited by 13 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our literature search identified 26 studies (five case studies, 18 case series, one prospective single‐center investigation, and two randomized, double‐blinded, placebo‐controlled pilot studies) comprising 185 (results reported on 174) patients, with a median of four, ranging from 1 to 21 patients exploring omalizumab treatment for recalcitrant AD. A total of 129 (74.1%) patients experienced a beneficial effect of treatment ranging from little to complete response (Table ) . Forty‐five patients (25.9%) from seven different studies reported no or negative effect off omalizumab treatment .…”

Section: Resultsmentioning

confidence: 99%

“…We and most other studies report no or very few side effects of treatment with omalizumab. Only eight studies reported side effects, and none of these were severe. The most common side effects were injection site reactions and headache, dizziness, and nausea .…”

Section: Discussionmentioning

confidence: 99%

“…Only eight studies reported side effects, and none of these were severe. The most common side effects were injection site reactions and headache, dizziness, and nausea . The most severe reaction was a vasovagal syncope and a hypotensive episode after the first dose .…”

Section: Discussionmentioning

confidence: 99%

“…The most common side effects were injection site reactions and headache, dizziness, and nausea . The most severe reaction was a vasovagal syncope and a hypotensive episode after the first dose . No studies reported dose‐dependent side effects.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Omalizumab for atopic dermatitis: case series and a systematic review of the literature

et al. 2016

View full text Add to dashboard Cite

Omalizumab is a recombinant humanized monoclonal antibody targeting the high-affinity Fc receptor of IgE, registered for the treatment of chronic spontaneous urticaria and severe allergic asthma. We present a case series of nine patients with atopic dermatitis (AD) treated off-label with omalizumab and a systematic review of the existing literature. Patients were selected consecutively from a tertiary dermatological referral center during a 5-year period. All patients were treated with omalizumab at a starting dose of 300 mg subcutaneously every 4 weeks. Systematic literature searches were performed in PubMed, Web of Science, EMBASE, and ClinicalTrials.gov to identify any study (case reports, case series, and controlled trials) evaluating the effect of treatment with omalizumab in AD. Based on physicians' assessment, 50% of our patients had a good or excellent response to treatment with omalizumab; a further 12.5% had a moderate response, while 37.5% experienced no response or deterioration of symptoms during treatment. Treatment was generally well tolerated. Twenty-six studies with a median of four patients each (range 1-21), comprising 174 patients, were included in the systematic review. Summed over all studies, a total of 129 patients (74.1%) experienced a beneficial effect of treatment ranging from little to complete response. Omalizumab appears to be a safe and well tolerated, however expensive, treatment with some clinical benefit in patients with severe recalcitrant AD. Recommendation for use in clinical practice awaits evidence from larger randomized controlled trials.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Omalizumab for atopic dermatitis: case series and a systematic review of the literature

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In 2012, Fernandez-Anton et al treated with omalizumab nine patients with severe atopic dermatitis refractory to at least two systemic drugs. All patients reported a decrease in pruritus and an improvement in quality of life [84].…”

Section: Skin Diseasesmentioning

confidence: 99%

Off-Label Uses of Omalizumab

El-Qutob¹

2015

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

The off-label use of medicines is a common and extensive clinical practice. Omalizumab has been licensed for use in severe allergic asthma and chronic urticaria. Omalizumab dosing was based on body weight and baseline serum IgE concentration. All patients are required to have a baseline IgE between 30 and 700 IU/ml and body weight not more than 150 kg. The use of off-label drugs may lead to several problems including adverse effects and an increased risk/benefit balance. In this article, there are summarized off-label uses of omalizumab in the last recent years in diseases in which IgE maybe or certainly has a corner role such as allergic rhinitis, allergic bronchopulmonary aspergillosis, anaphylaxis, keratoconjunctivitis, food allergy, drug allergy, urticaria, angioedema, non-atopic asthma, atopic dermatitis, nasal polyps, Churg-Strauss syndrome, eosinophilic otitis media, chronic rhinosinusitis, bullous pemphigoid, contact dermatitis, and others. Use in pregnancy asthmatic women and pre-co-administration with specific immunotherapy will also be revised.

show abstract